Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has shown significant stock performance, with shares increasing by 53% over the past year and 15% year-to-date, attracting positive attention from analysts like Jim Cramer [2]. Financial Performance - RBC Capital raised Johnson & Johnson's share price target to $255 from $240, maintaining an Outperform rating, citing the company's strong financial position to handle legal challenges [2]. - Bank of America also increased its price target for Johnson & Johnson to $227 from $221, keeping a Neutral rating, and noted that the firm's organic growth is leading to healthier multiples [2]. - The company's projected full-year revenue for 2025 is $94.2 billion, reflecting a 6% growth, with expectations to reach $100.5 billion in 2026 [2]. Analyst Sentiment - Jim Cramer expressed strong optimism about Johnson & Johnson, highlighting the company's cancer drug portfolio and orthopedic spinoff as key factors driving his positive outlook [2][5].